The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity
Open accessAbstract
The trace amine-associated receptor 1 (TAAR1), activated by endogenous metabolites of amino acids like the trace amines p-tyramine and β-phenylethylamine, has proven to be an important modulator of the dopaminergic system and is considered a promising target for the treatment of neuropsychiatric disorders. To decipher the brain functions of TAAR1, a selective TAAR1 agonist, RO5166017, was engineered. RO5166017 showed high affinity and potent functional activity at mouse, rat, cynomolgus monkey, and human TAAR1 stably expressed in HEK293 cells as well as high selectivity vs. other targets. In mouse brain slices, RO5166017 inhibited the firing frequency of dopaminergic and serotonergic neurons in regions where Taar1 is expressed (i.e., the ventral tegmental area and dorsal raphe nucleus, respectively). In contrast, RO5166017 did not change the firing frequency of noradrenergic neurons in the locus coeruleus, an area devoid of Taar1 expression. Furthermore, modulation of TAAR1 activity altered the desensitization rate and agonist potency at 5-HT 1A receptors in the dorsal raphe, suggesting that TAAR1 modulates not only dopaminergic but also serotonergic neurotransmission. In WT but not Taar1−/−mice, RO5166017 prevented stress-induced hyperthermia and blocked dopamine-dependent hyperlocomotion in cocaine-treated and dopamine transporter knockout mice as well as hyperactivity induced by an NMDA antagonist. These results tie TAAR1 to the control of monoamine-driven behaviors and suggest anxiolytic- and antipsychotic-like properties for agonists such as RO5166017, opening treatment opportunities for psychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A review of central 5-HT receptors and their function
Barnes, N. M., & Sharp, T. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00010-6 · Cited by 3,161
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., & Caron, M. G. (1996) · Nature · doi:10.1038/379606a0 · Cited by 2,476
Self-citationTrace amines: Identification of a family of mammalian G protein-coupled receptors
Borowsky, B., Adham, N., Jones, K. A., Raddatz, R., Artymyshyn, R., Ogozalek, K. L., Durkin, M. M., Lakhlani, P. P., Bonini, J. A., Pathirana, S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151105198 · Cited by 906
Bunzow, J. R., Sonders, M. S., Arttamangkul, S., Harrison, L. M., Zhang, G., Quigley, D. I., Darland, T., Suchland, K. L., Pasumamula, S., Kennedy, J. L., et al. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1181 · Cited by 648
Javitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009) · Science · doi:10.1126/science.1166127 · Cited by 535 · cited 1×
“However, all these ligands have TAAR1independent effects through other targets, such as the monoaminergic transporters and receptors or the σ-receptors (3, 11, 13, 16).”
Background3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone
Scanlan, T. S., Suchland, K. L., Hart, M. E., Chiellini, G., Huang, Y., Kruzich, P. J., Frascarelli, S., Crossley, D. A., Bunzow, J. R., Ronca-Testoni, S., et al. (2004) · Nature Medicine · doi:10.1038/nm1051 · Cited by 439
Monoamine Transporters: From Genes to Behavior
Gainetdinov, R. R., & Caron, M. G. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.050802.112309 · Cited by 381
Self-citationTrace Amine-Associated Receptor 1 Modulates Dopaminergic Activity
Lindemann, L., Meyer, C. A., Jeanneau, K., Bradaia, A., Ozmen, L., Bluethmann, H., Bettler, B., Wettstein, J. G., Borroni, E., Moreau, J.-L., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.132647 · Cited by 348
Self-citationImproving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors
Millan, M. J. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38982-7 · Cited by 287
A renaissance in trace amines inspired by a novel GPCR family
Lindemann, L., & Hoener, M. C. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.007 · Cited by 287
Self-citationLindemann, L., Ebeling, M., Kratochwil, N. A., Bunzow, J. R., Grandy, D. K., & Hoener, M. C. (2005) · Genomics · doi:10.1016/j.ygeno.2004.11.010 · Cited by 278
Self-citationRole of Somatodendritic 5‐HT Autoreceptors in Modulating 5‐HT Neurotransmissiona
BLIER, P., PIÑEYRO, G., EL MANSARI, M., BERGERON, R., & DE MONTIGNY, C. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10192.x · Cited by 261
Adriaan Bouwknecht, J., Olivier, B., & Paylor, R. E. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.02.002 · Cited by 256
Bradaia, A., Trube, G., Stalder, H., Norcross, R. D., Ozmen, L., Wettstein, J. G., Pinard, A., Buchy, D., Gassmann, M., Hoener, M. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906522106 · Cited by 250
Self-citationMiller, G. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07109.x · Cited by 249
The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia
Wolinsky, T. D., Swanson, C. J., Smith, K. E., Zhong, H., Borowsky, B., Seeman, P., Branchek, T., & Gerald, C. P. (2007) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2006.00292.x · Cited by 245
The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain
Burchett, S. A., & Hicks, T. P. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.07.003 · Cited by 217
Trace amine-associated receptor 1—Family archetype or iconoclast?
Grandy, D. K. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.007 · Cited by 197
Gardier, A., Malagié, I., Trillat, A., Jacquot, C., & Artigas, F. (1996) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.1996.tb00145.x · Cited by 197
Stress-Induced Hyperthermia in Singly Housed Mice
Van Der Heyden, J. (1997) · Physiology & Behavior · doi:10.1016/s0031-9384(97)00157-1 · Cited by 192
Burden, D. A., & Philips, S. R. (1980) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1980.tb11267.x · Cited by 181
Trace Amine-Associated Receptor 1 Is a Modulator of the Dopamine Transporter
Xie, Z., & Miller, G. M. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.117382 · Cited by 157
The Potential of Trace Amines and Their Receptors for Treating Neurological and Psychiatric Diseases
Berry, M. D. (2007) · Reviews on Recent Clinical Trials · doi:10.2174/157488707779318107 · Cited by 138
Hart, M. E., Suchland, K. L., Miyakawa, M., Bunzow, J. R., Grandy, D. K., & Scanlan, T. S. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0505718 · Cited by 127
The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator
Sotnikova, T. D., Beaulieu, J., Espinoza, S., Masri, B., Zhang, X., Salahpour, A., Barak, L. S., Caron, M. G., & Gainetdinov, R. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013452 · Cited by 114
Self-citationPanas, H. N., Lynch, L. J., Vallender, E. J., Xie, Z., Chen, G. L., Lynn, S. K., Scanlan, T. S., & Miller, G. M. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22367 · Cited by 91
Sustained antidepressant effect of PEA replacement
SABELLI, H. C., Fink, P., FAWCETT, J. A., & Tom, C. (1996) · Journal of Neuropsychiatry · doi:10.1176/jnp.8.2.168 · Cited by 80
Dopamine transporter‐dependent and ‐independent actions of trace amine β‐phenylethylamine
Sotnikova, T. D., Budygin, E. A., Jones, S. R., Dykstra, L., Caron, M. G., & Gainetdinov, R. R. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02721.x · Cited by 78
Self-citationPhenylethylamine modulation of affect: therapeutic and diagnostic implications
SABELLI, H. C., & Javaid, J. I. (1995) · Journal of Neuropsychiatry · doi:10.1176/jnp.7.1.6 · Cited by 78
Millan, M. J., Dekeyne, A., Newman‐Tancredi, A., Cussac, D., Audinot, V., Milligan, G., Duqueyroix, D., Girardon, S., Mullot, J., Boutin, J. A., et al. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39022-6 · Cited by 63
Boulay, D., Bergis, O. E., Avenet, P., & Griebel, G. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.144 · Cited by 48
Correction: The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator
Sotnikova, T. D., Beaulieu, J., Espinoza, S., Masri, B., Zhang, X.-D., Salahpour, A., Barak, L. S., Caron, M. G., & Gainetdinov, R. R. (2010) · PLoS ONE · doi:10.1371/annotation/a2019934-b1cc-4781-80cb-9e09fc7ff6dc · Cited by 33
Self-citationModulation of stress by imidazoline binding sites: Implications for psychiatric disorders
Smith, K. L., Jessop, D. S., & Finn, D. P. (2008) · Stress · doi:10.1080/10253890802302908 · Cited by 31
Trace amines depress D2‐autoreceptor‐mediated responses on midbrain dopaminergic cells
Ledonne, A., Federici, M., Giustizieri, M., Pessia, M., Imbrici, P., Millan, M. J., Bernardi, G., & Mercuri, N. B. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00792.x · Cited by 26
Alberati, D., Moreau, J., Mory, R., Pinard, E., & Wettstein, J. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.016 · Cited by 20
Self-citation
Cited by
Dopamine: Functions, Signaling, and Association with Neurological Diseases
Klein, M. O., Battagello, D. S., Cardoso, A. R., Hauser, D. N., Bittencourt, J. C., & Correa, R. G. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0632-3 · Cited by 1,073
Pharmacological characterization of designer cathinones in vitro
Simmler, L., Buser, T., Donzelli, M., Schramm, Y., Dieu, L., Huwyler, J., Chaboz, S., Hoener, M., & Liechti, M. (2013) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02145.x · Cited by 672
Self-citationDopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Dopamine receptors –IUPHAR R eview 13
Beaulieu, J., Espinoza, S., & Gainetdinov, R. R. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12906 · Cited by 521
Self-citationReceptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
Self-citation
Metadata
- Authors
- Revel, F. G., Moreau, J.-L., Gainetdinov, R. R., Bradaia, A., Sotnikova, T. D., Mory, R., Durkin, S., Zbinden, K. G., Norcross, R., Meyer, C. A., Metzler, V., Chaboz, S., Ozmen, L., Trube, G., Pouzet, B., Bettler, B., Caron, M. G., Wettstein, J. G., & Hoener, M. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-04-27
- Volume
- 108
- Issue
- 20
- Pages
- 8485-8490
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2142137999
- Cited by
- 364
- References
- 37
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.